440 related articles for article (PubMed ID: 35104168)
1. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
3. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics.
Kumar S; Plotnikov NV; Rouse JC; Singh SK
J Pharm Pharmacol; 2018 May; 70(5):595-608. PubMed ID: 28155992
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
6. How can we discover developable antibody-based biotherapeutics?
Bauer J; Rajagopal N; Gupta P; Gupta P; Nixon AE; Kumar S
Front Mol Biosci; 2023; 10():1221626. PubMed ID: 37609373
[TBL] [Abstract][Full Text] [Related]
7. The Therapeutic Antibody Profiler for Computational Developability Assessment.
Raybould MIJ; Deane CM
Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
[TBL] [Abstract][Full Text] [Related]
8. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
9. Blueprint for antibody biologics developability.
Mieczkowski C; Zhang X; Lee D; Nguyen K; Lv W; Wang Y; Zhang Y; Way J; Gries JM
MAbs; 2023; 15(1):2185924. PubMed ID: 36880643
[TBL] [Abstract][Full Text] [Related]
10. Assessing developability early in the discovery process for novel biologics.
Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
[TBL] [Abstract][Full Text] [Related]
11. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
12. Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences.
Coffman J; Marques B; Orozco R; Aswath M; Mohammad H; Zimmermann E; Khouri J; Griesbach J; Izadi S; Williams A; Sankar K; Walters B; Lin J; Hepbildikler S; Schiel J; Welsh J; Ferreira G; Delmar J; Mody N; Afdahl C; Cui T; Khalaf R; Hanke A; Pampel L; Parimal S; Hong X; Patil U; Pollard J; Insaidoo F; Robinson J; Chandra D; Blanco M; Panchal J; Soundararajan S; Roush D; Tugcu N; Cramer S; Haynes C; Willson RC
Biotechnol Bioeng; 2020 Jul; 117(7):2100-2115. PubMed ID: 32255523
[TBL] [Abstract][Full Text] [Related]
13. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.
Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z
Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767
[TBL] [Abstract][Full Text] [Related]
14. Biophysical properties of the clinical-stage antibody landscape.
Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
[TBL] [Abstract][Full Text] [Related]
15. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
Makowski EK; Wu L; Gupta P; Tessier PM
MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
[TBL] [Abstract][Full Text] [Related]
16. Structure, heterogeneity and developability assessment of therapeutic antibodies.
Xu Y; Wang D; Mason B; Rossomando T; Li N; Liu D; Cheung JK; Xu W; Raghava S; Katiyar A; Nowak C; Xiang T; Dong DD; Sun J; Beck A; Liu H
MAbs; 2019; 11(2):239-264. PubMed ID: 30543482
[TBL] [Abstract][Full Text] [Related]
17. Developability assessment during the selection of novel therapeutic antibodies.
Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
[TBL] [Abstract][Full Text] [Related]
18. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
Thorsteinson N; Comeau SR; Kumar S
Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
[TBL] [Abstract][Full Text] [Related]
20. DOTAD: A Database of Therapeutic Antibody Developability.
Li W; Lin H; Huang Z; Xie S; Zhou Y; Gong R; Jiang Q; Xiang C; Huang J
Interdiscip Sci; 2024 Mar; ():. PubMed ID: 38530613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
